ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,246.97
0.08%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Nautilus Biotechnology Inc (NAUT)

  7. Nautilus Biotechnology Inc (NAUT) News

Nautilus Biotechnology (NAUT)

Nautilus Biotechnology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NAUT
DateTimeSourceHeadlineSymbolCompany
13/06/202421:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAUTNautilus Biotechnology Inc
23/05/202413:00GlobeNewswire Inc.Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:NAUTNautilus Biotechnology Inc
30/04/202413:00GlobeNewswire Inc.Nautilus Biotechnology Reports First Quarter 2024 Financial ResultsNASDAQ:NAUTNautilus Biotechnology Inc
11/04/202413:00GlobeNewswire Inc.Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024NASDAQ:NAUTNautilus Biotechnology Inc
07/03/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NAUTNautilus Biotechnology Inc
06/03/202421:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NAUTNautilus Biotechnology Inc
05/03/202421:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAUTNautilus Biotechnology Inc
05/03/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAUTNautilus Biotechnology Inc
05/03/202421:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAUTNautilus Biotechnology Inc
05/03/202421:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAUTNautilus Biotechnology Inc
05/03/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAUTNautilus Biotechnology Inc
28/02/202413:00GlobeNewswire Inc.Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsNASDAQ:NAUTNautilus Biotechnology Inc
28/02/202412:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAUTNautilus Biotechnology Inc
28/02/202412:25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NAUTNautilus Biotechnology Inc
28/02/202412:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NAUTNautilus Biotechnology Inc
28/02/202412:04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NAUTNautilus Biotechnology Inc
28/02/202412:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAUTNautilus Biotechnology Inc
22/02/202413:00GlobeNewswire Inc.Nautilus Biotechnology to Participate in the TD Cowen 44áµ—Ê° Annual Healthcare ConferenceNASDAQ:NAUTNautilus Biotechnology Inc
07/02/202413:00GlobeNewswire Inc.Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024NASDAQ:NAUTNautilus Biotechnology Inc
14/12/202321:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAUTNautilus Biotechnology Inc
30/11/202313:00GlobeNewswire Inc.Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics AwardNASDAQ:NAUTNautilus Biotechnology Inc
01/11/202312:05GlobeNewswire Inc.Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell DevelopmentNASDAQ:NAUTNautilus Biotechnology Inc
31/10/202320:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAUTNautilus Biotechnology Inc
31/10/202312:05GlobeNewswire Inc.Nautilus Biotechnology Reports Third Quarter 2023 Financial ResultsNASDAQ:NAUTNautilus Biotechnology Inc
11/10/202313:05GlobeNewswire Inc.Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023NASDAQ:NAUTNautilus Biotechnology Inc
06/09/202312:30GlobeNewswire Inc.Nautilus Biotechnology to Participate in Upcoming September Investor ConferencesNASDAQ:NAUTNautilus Biotechnology Inc
04/08/202313:00GlobeNewswire Inc.Nautilus Biotechnology to Participate in Upcoming August Investor ConferencesNASDAQ:NAUTNautilus Biotechnology Inc
02/08/202321:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAUTNautilus Biotechnology Inc
02/08/202312:30GlobeNewswire Inc.Nautilus Biotechnology Reports Second Quarter 2023 Financial ResultsNASDAQ:NAUTNautilus Biotechnology Inc
11/07/202314:23GlobeNewswire Inc.Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023NASDAQ:NAUTNautilus Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:NAUT

Your Recent History

LSE
PANR
Pantheon Resources
LSE
BIRD
Blackbird
LSE
AV.
Aviva
LSE
SRT
Srt Marine Systems
LSE
ZED
Zenova
LSE
TLW
Tullow Oil
LSE
NEXN
Nexxen
LSE
GOLD
LSE
ENET
Ethernity Networks
LSE
NSCI
Netscientific
LSE
MKS
Marks And Spencer
LSE
SQZ
Serica Energy
LSE
VAST
Vast Resources
LSE
ULT
Ultrasis
LSE
LBE
Longboat Energy
LSE
TW.
Taylor Wimpey
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved